[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse MAEA

Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus matrix Cell membrane Cytoplasm, cytoskeleton Note=Localized as nuclear speckled-like pattern.
Domain PF10607 CTLH/CRA C-terminal to LisH motif domain
Function

Plays a role in erythroblast enucleation and in the development of the mature macrophages. Mediates the attachment of erythroid cell to mature macrophages, in correlation with the presence of MAEA at cell surface of mature macrophages; This MAEA-mediated contact inhibits erythroid cells apoptosis. Participates in erythroblastic island formation, which is the functional unit of definitive erythropoiesis. Associates with F-actin to regulate actin distribution in erythroblasts and macrophages. May contribute to nuclear architecture and cells division events.

> Gene Ontology
 
Biological Process GO:0002262 myeloid cell homeostasis
GO:0007346 regulation of mitotic cell cycle
GO:0010498 proteasomal protein catabolic process
GO:0021700 developmental maturation
GO:0030099 myeloid cell differentiation
GO:0030218 erythrocyte differentiation
GO:0033028 myeloid cell apoptotic process
GO:0033032 regulation of myeloid cell apoptotic process
GO:0033033 negative regulation of myeloid cell apoptotic process
GO:0034101 erythrocyte homeostasis
GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process
GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process
GO:0043249 erythrocyte maturation
GO:0043353 enucleate erythrocyte differentiation
GO:0048469 cell maturation
GO:0048821 erythrocyte development
GO:0048822 enucleate erythrocyte development
GO:0048872 homeostasis of number of cells
GO:0061515 myeloid cell development
Molecular Function GO:0003779 actin binding
GO:0004842 ubiquitin-protein transferase activity
GO:0019787 ubiquitin-like protein transferase activity
Cellular Component GO:0005819 spindle
GO:0005826 actomyosin contractile ring
GO:0005938 cell cortex
GO:0015629 actin cytoskeleton
GO:0016363 nuclear matrix
GO:0030863 cortical cytoskeleton
GO:0030864 cortical actin cytoskeleton
GO:0032153 cell division site
GO:0032155 cell division site part
GO:0034399 nuclear periphery
GO:0034657 GID complex
GO:0044448 cell cortex part
GO:0070938 contractile ring
GO:0099568 cytoplasmic region
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between MAEA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of MAEA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: -3.00; FDR: 0.02000 Resistant to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 STARS Score: 4.88; FDR: 0.003 Resistant to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX STARS Score: 3.55; FDR: 0.047 Resistant to T cell-mediated killing
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of MAEA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2190.352
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2050.93
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2230.902
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1720.574
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3740.861
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0840.975
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0730.831
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0740.961
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2540.882
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4360.79
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.7740.748
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1030.141
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of MAEA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47500500.109
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MAEA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MAEA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MAEA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MAEA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of MAEA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between MAEA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolMAEA
Namemacrophage erythroblast attacher
Aliases EMP; GID9; GID complex subunit 9, FYV10 homolog (S. cerevisiae); EMLP; HLC-10; GID complex subunit 9, FYV10 ......
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting MAEA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting MAEA.
ID Name Drug Type Targets #Targets
DB05389WF10Small MoleculeCD163, MAEA2